Table 4 Response results in the intent-to-treat population

From: A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer

 

Arm A

Arm B

Arm C

Arm D

 

N

%

N

%

N

%

N

%

Complete response

0

0

0

0

0

0

1

2

Partial response

3

7

2

5

5

11

1

2

Stable disease

18

44

23

62

25

54

19

43

Progressive disease

19

46

7

19

15

33

15

34

Not evaluable

1

2

5

14

1

2

8

18

Overall response (CR+PR)

3

7

2

5

5

11

2

5

95% confidence interval

1.5–19.9

0.7–18.2

3.6–23.6

0.6–15.5

Back to article page